Tarsus Pharmaceuticals (TARS) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$401.8 million.
- Tarsus Pharmaceuticals' Enterprise Value fell 2678.17% to -$401.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$401.8 million, marking a year-over-year decrease of 2678.17%. This contributed to the annual value of -$291.4 million for FY2024, which is 2811.0% down from last year.
- According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Enterprise Value is -$401.8 million, which was down 2678.17% from -$381.1 million recorded in Q2 2025.
- In the past 5 years, Tarsus Pharmaceuticals' Enterprise Value ranged from a high of -$156.2 million in Q1 2021 and a low of -$407.9 million during Q1 2025
- In the last 5 years, Tarsus Pharmaceuticals' Enterprise Value had a median value of -$227.4 million in 2023 and averaged -$254.1 million.
- As far as peak fluctuations go, Tarsus Pharmaceuticals' Enterprise Value plummeted by 23261.5% in 2021, and later surged by 2737.25% in 2023.
- Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Enterprise Value stood at -$171.8 million in 2021, then decreased by 26.31% to -$217.0 million in 2022, then decreased by 4.8% to -$227.4 million in 2023, then fell by 28.11% to -$291.4 million in 2024, then crashed by 37.91% to -$401.8 million in 2025.
- Its Enterprise Value was -$401.8 million in Q3 2025, compared to -$381.1 million in Q2 2025 and -$407.9 million in Q1 2025.